

DATE:	2021 May 3
TO:	Clinicians in All Zones
FROM:	Clinical Biochemistry Section, Alberta Precision Laboratories (APL)
RE:	Transfer of Tests from MitogenDx to APL

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective **May 11th**, the following tests currently performed at MitogenDx will now be performed by APL:

MitogenDx Test	Corresponding test performed by APL:
Anti-cellular antibodies by indirect immunofluorescence microscopy and International Consensus on ANA Patterns (ICAP) style reporting	Anti-nuclear antibodies by indirect immunofluorescence microscopy and ICAP style reporting
Anti-dsDNA	Anti-dsDNA
Systemic lupus profile: dsDNA, chromatin, Ribo-P, Ro52/TRIM21, SSA/Ro60, SSB/La, Sm, U1RNP, PCNA, Ku	Extractable nuclear antigen antibodies: dsDNA, chromatin, Ribo-P, Ro52/TRIM21, SSA/Ro60, SSB/La, CENPB, Sm, SmRNP, RNP68, RNPA, Scl-70, Jo-1
Sjögren's syndrome profile: SSA/Ro-52/TRIM21, SSA/Ro-60, SSB/La	Extractable nuclear antigen antibodies
Arthritis panel anti-HCP1-2/anti-VCP1-2, RF	Cyclic citrullinated peptide antibodies
Anti-neutrophil cytoplasmic antibody (anti-MPO, -PR3)	Anti-neutrophil cytoplasmic antibody (ANCA indirect immunofluorescence; anti-MPO, -PR3)
Anti-GAD65	Anti-GAD65 (subject to approval based on history of elevated diabetes markers or physician specialty such as neurology and rheumatology.)
Anti-Histone	Anti-Histone (HISA)
Inflammatory Bowel Disease profile ASCA (IgG + IgA)	Anti-Saccharomyces Cerevisiae Antibodies (ASCA) (IgG + IgA)

The following tests will be performed at APL **first** and referral requests will need to be approved:

Atypical ANCA: anti-elastase, anti-LAMP-2	Anti-neutrophil cytoplasmic antibody (ANCA indirect immunofluorescence; anti-MPO, -PR3)
Anti-phospholipid syndrome (anti-domain 1 beta-2 glycoprotein, PS/PT IgG/IgM;	Anti-beta-2-glycoprotein IgG Anti-cardiolipin antibody IgG

Importance/Impact

- This change will increase the efficiency of laboratory collections and reporting, decrease turn-around-time and duplication of tests.

Background

- As APL is mandated to provide publically funded laboratory testing in Alberta, the above tests will be performed by the Diagnostic and Scientific Centre in Calgary or University of Alberta Hospital in Edmonton.



Inquiries and Approval may be directed to

- Alex C. Chin, PhD DABCC FAACC FCACB, Clinical Biochemist, South Sector, alex.chin@aplabs.ca, 403-770-3222
- Kareena Schnabl, PhD FCACB, Clinical Biochemist, North Sector, kareena.schnabl@aplabs.ca, 780-407-3186

This memorandum has been reviewed and approved by

- Hossein Sadrzadeh, PhD, DABCC, FAACC, Clinical Section Chief, Clinical Biochemistry, South Sector
- Kareena Schnabl, MSc, PhD, FCACB, Clinical Section Chief, Clinical Biochemistry, North Sector
- Carolyn O'Hara, MD FRCPC, Interim Chief Medical Laboratory Officer